- In April 2024, Medtronic plc announced the global launch of its next-generation micro guide catheter, Echelon 10, designed for enhanced deliverability in neurovascular procedures. This catheter incorporates advanced coil compatibility and improved tracking for treating intracranial aneurysms. The launch represents Medtronic’s continued focus on innovation in minimally invasive neuro-interventional therapies and its effort to expand precision tools for complex cerebrovascular navigation
- In March 2024, Stryker Corporation unveiled its expanded Target Nano Detachable Coil System in Europe and Asia-Pacific markets, optimized for use with high-performance micro guide catheters in neurovascular embolization. The product line is designed to work with ultra-low profile microcatheters, enabling safe treatment of small and tortuous vessels. This expansion enhances Stryker’s neurovascular product ecosystem and reinforces its global market leadership in endovascular solutions
- In February 2024, Terumo Corporation launched a new version of its Progreat Microcatheter System with enhanced pushability and hydrophilic coating for use in complex peripheral interventions. Designed to improve access to distal lesions in lower limb ischemia and AV malformations, the catheter supports physicians performing high-precision therapeutic procedures. This development aligns with Terumo’s strategic focus on vascular health and procedural excellence
- In January 2024, Penumbra, Inc. received FDA clearance for its RED 72 microcatheter, developed specifically for large-vessel aspiration in stroke management. The microcatheter features optimized inner lumen geometry and a flexible distal tip to improve trackability and clot removal efficiency. This regulatory milestone strengthens Penumbra’s neurointerventional portfolio and supports broader access to advanced stroke treatment options
- In December 2023, Boston Scientific Corporation announced the acquisition of Relievant Medsystems, including its catheter technologies used in targeted spinal therapies. While not limited to vascular use, this acquisition reflects a trend toward multi-specialty catheter development and underscores Boston Scientific’s intent to diversify its microcatheter applications across both neurological and structural systems. The integration is expected to stimulate innovation in specialized microcatheter platforms adaptable across therapeutic areas
